What is the appropriate treatment for infections caused by Salmonella, Shigella, Campylobacter, and Escherichia coli?

Treatment of Salmonella, Shigella, Campylobacter, and E. coli Infections

Most cases of Salmonella, Campylobacter, and non-Shiga toxin-producing E. coli gastroenteritis should NOT receive antibiotics, as they are self-limited and treatment increases risks including prolonged bacterial shedding and resistance; however, Shigella infections and severe cases with high fever, bloody diarrhea, or immunocompromise warrant antimicrobial therapy 1.

General Approach to Treatment Decisions

The cornerstone of management for all four pathogens is supportive care with aggressive rehydration, as dehydration poses the greatest mortality risk, particularly in young children and elderly patients 1.

When to Withhold Antibiotics

For uncomplicated Salmonella gastroenteritis, antibiotics should be avoided because:

• They provide no clinical benefit in reducing diarrhea duration
• They significantly increase bacteriologic relapse (53% vs 0% with placebo) 2
• They prolong fecal shedding of organisms 1
• The infection is self-limited in immunocompetent hosts

For Campylobacter infections, antimicrobial benefit is minimal, and treatment is not recommended for most proven cases 1.

Critical Exception: STEC/Shiga Toxin-Producing E. coli

Antibiotics must be avoided in STEC O157 and any STEC producing Shiga toxin 2 (or when toxin genotype is unknown) 1. This is a strong recommendation with moderate-quality evidence showing:

• Fluoroquinolones, β-lactams, trimethoprim-sulfamethoxazole, and metronidazole cause harm
• Treatment increases risk of hemolytic uremic syndrome (HUS)
• Even macrolides should be avoided despite limited data, given insufficient evidence of benefit and potential harm

The mechanism involves antibiotic-induced bacterial lysis releasing more Shiga toxin. Shiga toxin 2 (stx2) is associated with increased risk of both bloody diarrhea and HUS 1.

When Antibiotics ARE Indicated

Shigella Infections

Unlike the other three pathogens, Shigella should generally be treated with antibiotics when identified, as it causes invasive dysentery with significant morbidity 1.

Severe or High-Risk Cases Requiring Treatment

Empiric antimicrobial therapy is warranted for:

Clinical indicators:

• Fever with bloody or mucoid diarrhea
• Severe abdominal cramping or tenderness
• Signs of sepsis or systemic toxicity
• Symptoms persisting beyond 5-6 days

Host factors:

• Immunocompromised patients (HIV/AIDS, transplant recipients, chemotherapy)
• Infants <3 months of age (particularly for Salmonella, which has higher bacteremia risk)
• Patients with hemolytic anemia or other high-risk conditions
• Suspected enteric fever (typhoid/paratyphoid) 1

Empiric Antibiotic Selection

For adults with severe inflammatory diarrhea:

• Fluoroquinolones (ciprofloxacin) OR
• Azithromycin
• Choice depends on local resistance patterns and travel history 1

For children:

• Third-generation cephalosporin for infants <3 months or those with neurologic involvement
• Azithromycin for others, based on local susceptibility 1

Critical Resistance Considerations

Increasing resistance is a major concern 3, 4:

• High rates of resistance to trimethoprim-sulfamethoxazole (>80-90% for Salmonella and Shigella in some regions)
• Emerging fluoroquinolone resistance, particularly in travel-associated cases
• Multidrug resistance (MDR) documented in 58-80% of isolates in recent studies 4
• Some strains now resistant to ciprofloxacin, azithromycin, AND ceftriaxone—the three first-line agents 3

This makes empiric treatment increasingly challenging and underscores the importance of obtaining cultures before treatment when feasible.

Specific Pathogen Guidance

Salmonella

• No antibiotics for uncomplicated gastroenteritis in immunocompetent hosts
• Treat if: age <3 months, immunocompromised, signs of bacteremia, or suspected enteric fever
• Blood cultures mandatory for infants <3 months and suspected enteric fever 1

Shigella

• Treat most cases given invasive nature
• Azithromycin or fluoroquinolones (based on susceptibility)
• Very low infectious dose (10-100 organisms) makes infection control critical

Campylobacter

• No antibiotics for most cases
• Consider treatment only in severe illness or immunocompromised hosts
• If treated, azithromycin preferred over fluoroquinolones due to resistance

E. coli

• STEC (O157 and Shiga toxin 2 producers): NEVER treat with antibiotics 1
• Non-STEC pathogenic E. coli: supportive care unless severe/immunocompromised
• Must distinguish STEC from other E. coli through Shiga toxin testing 1

Diagnostic Testing Requirements

Before considering antibiotics, obtain:

• Stool culture for Salmonella, Shigella, Campylobacter when fever, bloody stools, or severe symptoms present 1
• STEC testing via both culture (for O157) AND Shiga toxin/genomic assays (for non-O157) 1
• Blood cultures for infants <3 months, signs of sepsis, or suspected enteric fever 1

Common Pitfalls to Avoid

1. Never use motility inhibitors (loperamide) with STEC, suspected Shigella, or severe inflammatory diarrhea—they worsen outcomes 5

2. Don't assume antibiotic benefit—empiric treatment of acute bloody diarrhea shows only ~1 day symptom reduction but increases resistance and relapse risk 1

3. Don't miss STEC—any bloody diarrhea (even with fever) requires STEC evaluation before antibiotics 1

4. Don't forget travel history—resistance patterns vary dramatically by geographic exposure, particularly fluoroquinolone resistance from South Asia 1

5. Don't treat asymptomatic contacts of patients with bloody diarrhea—focus on infection control measures instead 1